The Grizzly, November 10, 2005

Congress to Campus • Spyware Protection • Honor Code Debate Continues • Human Rights Activist Speaks at UC • Scientific Sexual Healing • Epic Skate Shop • DiBlasio to Perform at Ursinus • Repeat! Dynasty Built in Second CC Crown • Fad Diets: Sometimes it is OK Not to be Trendy • Opinions: My Mouth Runneth Over; Who is Samuel Alito? • No Crown but Earn Bid to ECAC • Women\u27s Rugby Division III Championshttps://digitalcommons.ursinus.edu/grizzlynews/1699/thumbnail.jp

The Grizzly, December 8, 2005

Bomberger Gets a Face Lift • Ursinus Remembers Rosa Parks • Holiday Spotlight: Materialism vs. Family • Music to Celebrate By • It\u27s Spoken Word, Haven\u27t You Heard? • First Ever Ursinus College Bear Olympics Meets with Success • Holiday Fashion: What not to Wear • Misconceptions About Feminine Hygiene • Ursinus Professor Directs Performance at Prince Music Theater • Opinions: A Politically Correct Holiday Season; Flakes of Fury; Blog Addiction • Bears Beat at Buzzer • Guntli Leads Bears Past Bulletshttps://digitalcommons.ursinus.edu/grizzlynews/1702/thumbnail.jp

The Grizzly, November 17, 2005

Morgan Tyler McKinney Christened in Bomberger • Brewer\u27s Festival • March of Dimes / A.I.R. Awards • Say Hello to Carmella Greco • Sexual Engineering • The Examined Life Brings Memories of CIE • Opinions: A Call for Justice: The Fight Against Satire at Ursinus; It\u27s Your Bed, So Make It; Life: The Eight o\u27Clock Spanish Class; Why This Liberal Supports Samuel Alito • Bears Advance to Final Four • Spirits Still High After Season Opening Losshttps://digitalcommons.ursinus.edu/grizzlynews/1700/thumbnail.jp

The Grizzly, November 3, 2005

Remembering Professor McLennan: A Passionate Teacher and a Beloved Friend • Renowned Writer Speaks at Ursinus • Building Plans for Spring 2006 and Beyond • Ovarian Cancer Walk • Chikara Wrasslin\u27 • EQ vs. IQ: Hirsh-Pasek on Education • The Many Faces of Muslim Women • Take Heed and Use Your Keys • Escape Velocity\u27s Just the Start is a Great Success • New Oktoberfest Policies Put into Effect • Popping the Pill • RHA Brings Halloween Fun to Ursinus • Opinions: The Right to Write Right; Raising Rates for Resident Assistants; Global Gag Rule and FGM; Harriet Miers: Aftermath; You Snooze, You Lose • Title Hopes Still Alive as Ursinus Upsets #16 Johns Hopkins • Bears Beat Blue Jays, Look to Defend Conference Crownhttps://digitalcommons.ursinus.edu/grizzlynews/1698/thumbnail.jp

The Grizzly, October 13, 2005

Rain Dampens, But Fails to Quench, Family Day • UC Tuition Series Part 3: Financial Aid and Scholarships • All in the Timing Opens with Great Aplomb • Program Spotlight: International Film Festival • Internet Feud • Don Asher Speaks on Getting Into Grad School • Interview with The Abercrombie Couple • Texas Hold \u27Em Wins Over Ursinus Students • Why Run When You Can Walk? • Taking Care of an Embarrassing Problem • A New Band of Brothers Comes to Ursinus • Trail Travel • A Great Halloween Costume is Right Around the Corner • Child Development Expert Lectures • Atlantic Monthly\u27s James Fallows to Speak at Ursinus • Opinions: Look, Mom, No Hips!; Laughter is the Best Medicine; Cronyism; I Wonder How Long This One Will Last • Independent Film Producer Nadine Patterson to Speak at Ursinus • Baney Boots Bears Over Newport News • Field Hockey Ranked #1 in Nation • Women\u27s Rugby Drenches Lebanon Valleyhttps://digitalcommons.ursinus.edu/grizzlynews/1696/thumbnail.jp

The Grizzly, October 6, 2005

UC Tuition Series Part Two: AFAC • Thinking Man\u27s Comic Brings Biting Wit to Campus • Director of Physical Facilities Retires after 26 Years of Service • Crossing Woes • Long-term Campus Development Plans • Environmentalist Speaks on Climate Change • Program Spotlight: America Reads • Jordanian Visitor Discusses Education • New Attendance Policy • Battle of the Websites: The Facebook vs. MySpace • Let\u27s Talk About Sex • Staff Profile: Campus Safety Director Kim Taylor • Can You Climb the Wall? • Let\u27s Party: The Unspoken Rules of Ursinus Nightlife • Opinions: The Black Spotlight, Or Why White People Like Me; Stress Can Affect Your Academic Performance; Down the Path; Another Glance at UC Fringe • Bears Terrorize McDaniel in OT • Bears Make Bullets Shoot Blanks • Rally Falls Short as McDaniel Beats Ursinus • Soccer Struggles Continuehttps://digitalcommons.ursinus.edu/grizzlynews/1695/thumbnail.jp

The Grizzly, September 22, 2005

Oktoberfest Location Still Up in the Air • Activities Fair Showcases Clubs Both New and Old • WVOU Relaunch • Fringe Festival Comes to Kaleidoscope • Theft on Campus • Writing Center Opens • Soldier Speaks on Rebuilding Afghanistan • New Mac Lab in Ritter • The Dirt on UC Soap • UC Getting Greener Every Year • Ursinus in Florence: A Little Rain Never Hurt Anyone • Get Up and Get Moving: Making Exercise a Routine • Creating Communication Elation • Staff Profile: Gary Hodgson • Opinions: Veggie Monster? A Commentary on Society Brought to You by the Letter H; Religion of Ritual; The Next Generation; Priorities; Hard vs. Soft News • Ursinus Triumphs Over LaSalle • Bears Dominate Dickinson • Athletic Facility Face Lift • Tumblebears at UChttps://digitalcommons.ursinus.edu/grizzlynews/1693/thumbnail.jp

The Grizzly, September 29, 2005

Fire Safety on Campus • UC Tuition Series Part I: An Overview • Study Abroad in Madrid Returns • Campus Drive Removal • Upcoming RHA Events • Backed Up Your Computer Lately? • Club Spotlight: Le Cercle Francais • Seven Day Itch • The Drift Away Cafe • Main Street Walks for STD Awareness • Sigma Gamma Rho Walks for Sickle Cell Anemia • Update from Mexico • Heefner Organ Recital Series at Ursinus College • Readjusting: Tulane Students at Ursinus • Oktoberfest: An Ursinus Tradition • How do You Take Your Caffeine? • Opinions: Activities Fair Helps Students Get Involved; Face Off; Gangsta Mentality; This Year\u27s Fringe Festival Lived Up to its Name • Just for Kicks, Lady Bears Win Six • Bears Strand Shorewomen • Breaking the Moldhttps://digitalcommons.ursinus.edu/grizzlynews/1694/thumbnail.jp

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac